Cognoptix reaches halfway point of pre-pivotal clinical trial of drug/device test designed to identify Alzheimer’s disease via beta amyloid signature in the eyes
2013-04-09
- ACTON, Mass. -- Cognoptix announced today that it has reached the halfway point in a multi-site clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes. By detecting a specific fluorescent signature of ligand-marked beta-amyloid in the supranucleus region of the human lens, SAPPHIRE II achieved a two-fold differentiation factor between a group of five healthy volunteers and a group of five patients diagnosed with probable Alzheimer's disease in a recent proof-of-concept clinical trial.
Cognoptix begins pre-pivotal clinical trial of its drug/device test designed to identify Alzheimer's disease
2013-02-28
- "Our SAPPHIRE II eye test is designed to transform the diagnosis and treatment of Alzheimer's disease." - Paul Hartung, President and CEO, Cognoptix ACTON, Mass.--(BUSINESS WIRE)--Cognoptix announced today that it has begun a 40-patient clinical trial of its SAPPHIRE II eye test designed to identify Alzheimer's disease patients via a beta amyloid ("Ab") signature in their eyes.
- Watch video explaining the technology and unmet need
Paul Hartung, Cognoptix:"Inventages has been a strong supporter in realizing the Cognoptix vision."
